Tumor Response

In DESTINY-Breast03, a head-to-head study vs T-DM1,

The majority of patients had a tumor response with ENHERTU1

Exploratory endpoint: Best percent change from baseline
in the sum of diameters of measurable tumors

Waterfall plots depicting tumor response for ENHERTU and T-DM1. Waterfall plots depicting tumor response for ENHERTU and T-DM1.

aOnly subjects with measurable disease at baseline and at least one postbaseline target lesion assessment are included.

Downloadable Resource for You:

    Take a closer look at the DESTINY-Breast03
    efficacy and safety data

T-DM1, ado-trastuzumab emtansine.